Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support.

Saved in:
Bibliographic Details
Title: Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support.
Authors: Brown R; Department of Medicine, Cleveland Clinic, Cleveland, OH, USA., Smith KE; Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA., Shanshal MM; Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA., Dimou A; Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA., Leventakos K; Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA., Parikh K; Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA., Mansfield AS; Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA., Molina JR; Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA., Goetz MP; Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA., Jatoi A; Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. jatoi.aminah@mayo.edu., Cathcart-Rake E; Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Source: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2025 Nov 26; Vol. 33 (12), pp. 1134. Date of Electronic Publication: 2025 Nov 26.
Publication Type: Journal Article
Journal Info: Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1433-7339
DOI:10.1007/s00520-025-10182-9